Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures
Brief Summary: This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures.

The study consisted of 4 phases for each patient Baseline phase:\[From Screening Week -8 (V1) to randomization visit at Week 0 (V2)\], Core phase \[from randomization at Week 0 (V2) to Week 18 (V11)\], Extension phase \[from Week 18 (V11) until 48 weeks after the last patient had completed the core phase\] and Post Extension phase \[from end of Extension phase to end of study\].


Options:
A: Arm Label: TSC Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: TSC 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: TSC 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Arm Label: NF1 Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: NF1 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: NF1 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Intervention Type: DRUG; Name: Skincerity; Assigned to Arm(s): NF1 Placebo Arm, TSC Placebo Arm | Intervention Type: DRUG; Name: Skincerity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 1% Arm, TSC 1% Arm | Intervention Type: DRUG; Name: Skinercity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 5% Arm, TSC 5% Arm
B: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin
D: Arm Label: Everolimus LT target of 3 - 7 ng/mL; Type: EXPERIMENTAL; Interventions: Drug: RAD001, Drug: Antiepileptic drug (1 to 3 only), Drug: open label RAD001 (only used for post-extension phase) | Arm Label: Everolimus HT target of 9 -15 ng/mL; Type: EXPERIMENTAL; Interventions: Drug: RAD001, Drug: Antiepileptic drug (1 to 3 only), Drug: open label RAD001 (only used for post-extension phase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drug (1 to 3 only), Drug: open label RAD001 (only used for post-extension phase) | Intervention Type: DRUG; Name: RAD001; Assigned to Arm(s): Everolimus HT target of 9 -15 ng/mL, Everolimus LT target of 3 - 7 ng/mL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Antiepileptic drug (1 to 3 only); Assigned to Arm(s): Everolimus HT target of 9 -15 ng/mL, Everolimus LT target of 3 - 7 ng/mL, Placebo | Intervention Type: DRUG; Name: open label RAD001 (only used for post-extension phase); Assigned to Arm(s): Everolimus HT target of 9 -15 ng/mL, Everolimus LT target of 3 - 7 ng/mL, Placebo

Answer: D